PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
By Holly Campbell | March 3, 2020
Yesterday, PhRMA submitted comments on the Department of Health & Human Services’ (HHS) 2021 Notice of Benefit and Payment Parameters proposed rule. The proposed rule would hurt patients’ ability...
Read More
Fact Check: HCCI analysis overstates medicine spending and prices
By Katie Koziara | February 19, 2020
A recent analysis from the Health Care Cost Institute (HCCI) on health care spending overestimates medicine spending and pricing and mischaracterizes the true drivers of health care spending in...
Read More
Cancer medicines cost twice as much at hospitals, study finds
By Katie Koziara | January 21, 2020
Cancer medicines cost nearly twice as much in hospital outpatient facilities than in physician offices in the commercial market, according to a new study from the Employee Benefit Research...
Read More
Nearly 50% of brand medicine spending goes to the supply chain and others
By Holly Campbell | January 9, 2020
Nearly 50% of total spending on brand medicines – the sum of all payments made at the pharmacy or paid on a claim to a health care provider – went to the supply chain and other entities in 2018,...
Read More
More evidence that medicine prices are growing at slowest rate in decades
By Holly Campbell | October 4, 2019
This week the White House Council of Economic Advisers (CEA) released yet another report showing that medicine prices are growing at the slowest rate in decades. The report, “Measuring...
Read More
Survey shows out-of-pocket costs top health care concern for voters
By Holly Campbell | October 2, 2019
A recent national survey of 800 registered voters conducted by Public Opinion Strategies shows that health insurance premiums, deductibles and copays are the top health care concerns for...
Read More
Four reasons why the radical Pelosi Plan is the wrong approach
By Tom Wilbur | September 24, 2019
Speaker of the House Nancy Pelosi recently unveiled a radical plan that would restrict and fundamentally change how patients access medicines in the United States. It would threaten our country’s...
Read More
Hospitals make 9 times more than physicians’ offices on provider-administered medicines
By Katie Koziara | September 10, 2019
A new study, conducted by the Partnership for Health Analytic Research (PHAR), found that hospitals retained 91% of the total profit on physician-administered medicines in the commercial market...
Read More
Three things to know about the Part D GAO report
By Nicole Longo | August 16, 2019
The Government Accountability Office (GAO) recently released a new report looking at Medicare Part D and the role of Pharmacy Benefit Managers (PBMs) in the program. While the report provides a...
Read More
Setting the record straight on international reference pricing
By Kevin Haninger | July 16, 2019
There’s been a lot of talk in Washington about how to help patients better access and afford their medicines. These are important discussions that will hopefully result in real affordability...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
